Both paclitaxel and S-1 are effective against gastric cancer, but the optimal regimen for combined chemotherapy with these drugs remains unclear. This phase I/II study was designed to determine ...

来自肿瘤治疗领域的研究人员报道了一例转移性乳腺癌患者在接受标准剂量紫杉醇（80 mg/m2）治疗12个月后出现单侧面神经麻痹的罕见病例。通过对比增强核磁共振成像（MRI）发现双侧面神经（VII）强化特征，研究团队系统排除了脑膜转移和特发性贝尔麻痹，最终确认紫杉醇相关颅神经毒性。该研究为化疗药物神经毒性谱系提供了重要临床证据，强调肿瘤患者出现颅神经症状时需进行药物不良反应的鉴别诊断。

Relacorilant plus nab-paclitaxel could be a new standard of care for platinum-resistant ovarian cancer, according to Alexander Olawaiye, MD.

Background: Intravenous (IV) paclitaxel is an effective treatment for breast cancer. Oral administration paclitaxel is preferable to IV regarding minimizing IV injections, anaphylactic reactions to ...

Background: The results of a randomized phase II trial of PC +/- bevacizumab (A) suggested improved activity for the combination of PCA when compared to PC alone (Johnson DH, et al JCO 2004). Grade 5 ...

The addition of carboplatin to paclitaxel improved pathologic complete response and EFS with no increase in secondary malignancies among patients with triple-negative breast cancer, randomized ...

Those with triple-negative breast cancer also had a better tumor response with oral paclitaxel plus encequidar, with a rate of 30.5%, compared with 20.2% in those who received IV paclitaxel.

Corcept Therapeutics CORT announced that it has submitted a new drug application (NDA) to the FDA seeking approval for its lead pipeline candidate, relacorilant, for treating a new indication. The ...

Standard paclitaxel contains Cremophor EL as a solvent, thus requiring premedication with high doses of antihistamines and corticosteroids, as well as prolonged infusion times.

Topotecan–paclitaxel–bevacizumab, as compared with topotecan–paclitaxel alone, was associated with a hazard ratio for death of 0.74 (95% CI, 0.53 to 1.05) (Figure 3D).